14 results on '"Forconi, Francesco"'
Search Results
2. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
3. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
4. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells
5. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells
6. CLL-088: Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials
7. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
8. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia
9. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM)
10. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
11. The variable regulatory B10 capacity of Chronic Lymphocytic Leukemias associates with B-cell receptor anergy and epigenetic programming
12. The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
13. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia
14. Origins of the malignant clone in typical Waldenstrom's macroglobulinemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.